The nitric oxide/cGMP signaling pathway in pulmonary hypertension.
This article briefly reviews the background of endothelium-dependent vasorelaxation, describes the nitric oxide/cGMP/protein kinase pathway and its role in modulating pulmonary vascular tone and remodeling, and describes three approaches that target the nitric oxide/cGMP pathway in the treatment of patients with pulmonary arterial hypertension.
Klinger
James R
JR
Division of Pulmonary Sleep and Critical Care Medicine, Rhode Island Hospital, 593 Eddy Street, Providence, RI 02903, USA. james_klinger@brown.edu
D000818:Animals; D049109:Cell Proliferation; D006152:Cyclic GMP / Q000502:physiology*; D042783:Endothelial Cells / Q000502:physiology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000503:physiopathology*; D009569:Nitric Oxide / Q000502:physiology*; D010879:Piperazines / Q000627:therapeutic use; D011687:Purines / Q000627:therapeutic use; D015398:Signal Transduction / Q000502:physiology*; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000627:therapeutic use; D014664:Vasodilation / Q000502:physiology; D014665:Vasodilator Agents / Q000627:therapeutic use
D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D009569:Nitric Oxide; D000068677:Sildenafil Citrate; D006152:Cyclic GMP